Introduction
The recent federal court decision rejecting Novo Nordisk’s challenge to Medicare’s drug price negotiation program marks one of the most consequential turning points in U.S. pharmaceutical policy since the enactment of the Inflation Reduction Act (IRA). For the first time in its history, Medicare has begun to negotiate directly with drug manufacturers to lower prices on some of the most expensive and widely used medications. This is a move the pharmaceutical industry has long resisted.
At the center of this legal and political battle stood Novo Nordisk, the Danish pharmaceutical giant behind Ozempic, Wegovy, and several insulin products targeted in the first round of CMS negotiations. Novo argued that the program violated constitutional protections and exceeded the government’s authority, but in October 2025, the Third Circuit Court of Appeals decisively rejected the company’s appeal, affirming lower court rulings that upheld Medicare’s right to proceed.
The outcome is more than a single company’s defeat. By denying the appeal, the court effectively solidified the federal government’s power to implement the negotiation process, a mechanism projected to save Medicare billions over the next decade. The decision also sends a signal to other drugmakers that judicial resistance to the Inflation Reduction Act (IRA) framework is waning.
This article explores how the court’s ruling strengthens Medicare’s negotiating position, why the timing matters, and what ripple effects beneficiaries, insurers, and the pharmaceutical industry can expect as the first negotiated prices take effect in 2026.
Background: Medicare Negotiation & Legal Challenge
When Congress passed the Inflation Reduction Act (IRA) in 2022, one of its most controversial provisions gave Medicare the power to negotiate prices directly with drug manufacturers – something the federal program had been prohibited from doing since its creation. The law authorized the Centers for Medicare & Medicaid Services (CMS) to identify high-spending drugs without generic or biosimilar competition and establish a “maximum fair price” through structured negotiations with manufacturers. The goal was to reduce costs for both the Medicare program and its beneficiaries while reining in prescription drug inflation.
The first negotiation list, announced in 2023, included ten medications with the highest Medicare expenditures. Among them were several insulin products manufactured by Novo Nordisk, one of the world’s largest diabetes drug companies. Novo’s inclusion was not surprising — its insulins, including NovoLog, Levemir, and Fiasp, represent billions in annual Medicare spending. Yet the company quickly mounted a legal challenge, arguing that the program violated both statutory and constitutional protections.
Novo’s lawsuit claimed that CMS improperly grouped drugs sharing the same active ingredient under one negotiation designation, exceeding the agency’s statutory authority. It also alleged that the program’s structure, forcing manufacturers to sign negotiation agreements or face massive excise taxes, amounted to an unconstitutional taking of property and compelled speech, since companies were forced to accept government-dictated pricing terms. Finally, Novo contended that the courts should have jurisdiction to review CMS’s selection decisions, which the government argued were explicitly shielded from judicial review under the IRA.
In October 2025, the Third Circuit Court of Appeals in Philadelphia upheld a lower court’s dismissal of Novo Nordisk’s case, joining other federal courts that have sided with the government in similar lawsuits filed by Merck, Bristol Myers Squibb, AstraZeneca, and Novartis. The appellate panel ruled unanimously that the IRA’s negotiation provisions fall well within Congress’s constitutional powers and that the statute’s judicial review bar prevents courts from second-guessing CMS’s drug selection and price-setting decisions.
The ruling effectively closes a key legal avenue for pharmaceutical companies hoping to derail or delay Medicare negotiations. With Novo Nordisk’s challenge defeated, the pathway is clear for CMS to finalize negotiated prices and begin implementation in January 2026. This milestone could permanently reshape how the U.S. government interacts with the pharmaceutical industry.
Why Now
The Third Circuit’s October 2025 ruling arrived at a pivotal moment, just as CMS was finalizing the first negotiated drug prices set to take effect in January 2026. For more than a year, the pharmaceutical industry’s legal challenges had cast uncertainty over whether the new pricing regime would launch on schedule. By rejecting Novo Nordisk’s appeal, the court removed that cloud of doubt and provided CMS with full legal authority to proceed.
The timing also matters for insurers and beneficiaries. Medicare Advantage and Part D plans are currently locking in their 2026 premiums and formularies, relying on projected savings from negotiated prices. With the court decision cementing the program’s legitimacy, those savings can now be built confidently into plan design, stabilizing premiums and cost sharing for millions of enrollees.
Significance of the Appeals Court Decision
The Third Circuit’s decision represents more than a legal victory for the federal government—it reaffirms the durability of the Inflation Reduction Act’s drug negotiation framework and cements CMS’s discretion to manage one of the most sweeping reforms in the history of Medicare. The ruling underscored two key legal principles: that Congress has clear constitutional authority to condition participation in federal programs on compliance with pricing requirements, and that the statute’s judicial review bar means courts cannot interfere with CMS’s administrative choices about which drugs to include or how to conduct negotiations.
By rejecting Novo Nordisk’s claims that the negotiation process amounted to “coerced participation” or “unconstitutional taking,” the panel reaffirmed that the program is voluntary in structure. Manufacturers remain free to decline negotiation, though doing so would make their products ineligible for Medicare coverage, a consequence the court viewed as lawful under Congress’s spending powers. This interpretation sharply limits the pharmaceutical industry’s ability to challenge the program on constitutional grounds.
The decision also provides critical regulatory stability for CMS and insurers. With the court affirming that CMS may group drugs sharing the same active ingredient—for instance, several insulin formulations sold under different trade names—the agency can avoid duplicative negotiations and secure more comprehensive discounts. This precedent will shape future negotiation rounds, including upcoming selections that may encompass GLP-1 agonists, anticoagulants, and oncology drugs.
Other drugmakers such as Merck, AstraZeneca, and Bristol Myers Squibb have pursued similar challenges in various jurisdictions. The Third Circuit’s strong, unanimous decision now makes it more difficult for those companies to succeed on appeal. The consistency of rulings across circuits also reduces the likelihood that the Supreme Court will intervene, giving CMS a firmer footing to continue negotiations without delay.
For the broader health-care market, the ruling signals that the Medicare drug negotiation regime is here to stay. It reassures insurers and actuaries that expected price reductions will materialize, guiding 2026 premium projections and formulary design. At the same time, it sends a warning to manufacturers that the legal window to resist participation is closing rapidly.
In practical terms, the decision transforms the IRA’s negotiation provisions from an experimental policy into an enforceable, precedent-protected structure. With judicial validation now secured, CMS can proceed with confidence to finalize negotiated prices, ensuring that by early 2026, the long-promised vision of federally negotiated Medicare drug prices will finally move from political debate to operational reality.
Potential Effects on Premiums, Copays & Drug Access
The practical consequences of the Third Circuit’s ruling will unfold most visibly in 2026, when the first ten negotiated drugs enter the market under Medicare’s “maximum fair price” model. For beneficiaries, this transition could reshape both premiums and out-of-pocket spending.
Since negotiated prices directly reduce what Medicare pays for high-cost drugs, those savings ripple through the system. Part D sponsors—the private insurers that administer prescription drug coverage—use these lower acquisition costs to calculate plan bids and set monthly premiums. If the negotiated discounts average the 35–60% range projected by CMS, beneficiaries could see modest premium reductions or slower growth compared with the pre-IRA trend. Lower prices may also enable plans to expand formularies or lower cost-sharing tiers for selected drugs, improving medication adherence and affordability.
The ruling also affects copayments and coinsurance. Under current Part D rules, beneficiaries pay a percentage of a drug’s negotiated price. A 40% reduction in list price translates directly into lower coinsurance for patients with chronic conditions like diabetes, heart disease, or cancer. For example, insulin users—many of whom have faced fluctuating out-of-pocket costs despite previous caps—may finally experience meaningful, sustained relief.
Still, the benefits will not be uniform. Plans differ in how they pass savings to enrollees, and some may restructure formularies to offset revenue losses from reduced rebates. Drug manufacturers might also respond by raising list prices in the commercial market or withdrawing older products from preferred coverage. These market adaptations could temper the full downstream benefit for non-Medicare populations.
Another consequence involves equity in access. The negotiation program is designed to prioritize drugs with the highest Medicare spending, which means that savings will concentrate among conditions most common in older adults. While this approach maximizes fiscal impact, it may leave patients with rarer or recently launched drugs still exposed to high costs until future negotiation rounds broaden eligibility.
Overall, the court’s ruling ensures that the first phase of negotiated pricing will proceed on time, giving plans the legal certainty to incorporate lower drug costs into their 2026 designs. Whether the savings translate into tangible consumer relief will depend on how efficiently insurers, PBMs, and CMS coordinate to deliver those benefits downstream.
Strategic Responses by Insurers, Manufacturers & CMS
With the courts closing the last major legal path to delay the Inflation Reduction Act’s drug price provisions, all three major stakeholders (insurers, manufacturers, and CMS) are rapidly recalibrating their strategies for 2026.
For insurers and pharmacy benefit managers (PBMs), the ruling brings long-awaited predictability. Many have already begun incorporating projected “maximum fair prices” into their actuarial bids for 2026 Part D and Medicare Advantage plans. Lower unit costs on high-spending drugs like insulin allow plans to restrain premium growth, offer richer coverage in other therapeutic classes, or expand low-income subsidy options. PBMs are also adjusting rebate contracts to align with negotiated pricing structures, effectively shifting their focus from rebate capture to cost-sharing optimization and adherence incentives.
Manufacturers, meanwhile, are entering a new era of risk management. Some companies—especially those facing immediate negotiation rounds—are preparing to engage fully with CMS rather than pursue further litigation. They are likely to revisit pricing strategies, anticipating the ripple effect on commercial markets and employer-sponsored plans. Others may redirect R&D and marketing investments toward drugs unlikely to face near-term negotiation, such as novel biologics or orphan therapies. Strategic portfolio diversification and early patent planning will become core business defenses.
For CMS, the decision empowers the agency to finalize price agreements with full legal backing. The agency’s next steps include expanding its negotiation infrastructure, refining transparency standards, and preparing for future rounds involving additional therapeutic areas. CMS must also balance cost containment with market stability, ensuring that aggressive price cuts do not trigger supply disruptions or discourage innovation.
The outcome signals a new equilibrium: manufacturers will adapt, insurers will optimize, and CMS will oversee a historic shift toward a more assertive, government-led drug pricing model. The Third Circuit’s ruling has transformed negotiation from a contested experiment into the operational center of U.S. pharmaceutical policy.
Conclusion
The rejection of Novo Nordisk’s appeal represents far more than a single corporate loss—it marks the judicial legitimization of Medicare’s authority to negotiate drug prices, a reform that had eluded policymakers for decades. By affirming the Inflation Reduction Act’s negotiation framework, the Third Circuit Court of Appeals effectively removed the final barrier to implementation, granting CMS the freedom to proceed without fear of judicial obstruction.
This decision sets the stage for the first negotiated prices to take effect in 2026, ushering in a new era of transparency and accountability in the U.S. drug market. For Medicare beneficiaries, the ruling holds tangible promise: lower premiums, smaller copayments, and improved access to vital medications like insulin and anticoagulants. For insurers, it provides the regulatory clarity needed to build sustainable benefit designs and premium forecasts.
For manufacturers, however, the message is unambiguous. The negotiation framework is here to stay. The path forward lies not in courtroom battles but in strategic adaptation: pricing smarter, innovating faster, and aligning with a system that now values affordability as much as innovation.
In retrospect, the Novo Nordisk case may be remembered as the moment when Medicare’s long-debated negotiating power evolved from policy theory into enforceable law—and when the balance of influence in U.S. drug pricing began to shift, decisively, toward patients and public payers.